Dane Leone
Stock Analyst at Raymond James
(2.36)
# 1,460
Out of 4,415 analysts
68
Total ratings
40.28%
Success rate
-0.24%
Average return
Main Sectors:
24 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $16.83 | +167.38% | 2 | Feb 21, 2024 | |
| BPMC Blueprint Medicines | Maintains: Strong Buy | $85 → $100 | $107.19 | -6.71% | 4 | Dec 22, 2023 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $40.20 | -25.37% | 1 | Nov 16, 2023 | |
| BLUE bluebird bio | Maintains: Outperform | $10 → $13 | $0.90 | +1,344.77% | 5 | Nov 8, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $957.00 | -0.73% | 7 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $7.53 | +72.64% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $27.83 | +65.29% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $29.09 | +137.19% | 4 | May 8, 2023 | |
| GTHX G1 Therapeutics | Maintains: Outperform | $24 → $8 | $4.49 | +78.17% | 4 | May 4, 2023 | |
| RLAY Relay Therapeutics | Upgrades: Strong Buy | $29 | $7.04 | +311.93% | 2 | Apr 19, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $1.70 | +370.59% | 2 | Nov 10, 2022 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $31 → $13 | $1.18 | +1,001.69% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $6.17 | +126.90% | 3 | Nov 8, 2022 | |
| XNCR Xencor | Upgrades: Strong Buy | $58 | $24.11 | +140.56% | 2 | Oct 13, 2022 | |
| SLP Simulations Plus | Maintains: Outperform | $54 → $70 | $46.72 | +49.83% | 2 | Aug 29, 2022 | |
| ALLO Allogene Therapeutics | Downgrades: Market Perform | n/a | $2.97 | - | 5 | Aug 10, 2022 | |
| CYTK Cytokinetics | Maintains: Outperform | $54 → $63 | $65.27 | -3.48% | 2 | Aug 5, 2022 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Market Perform | n/a | $43.99 | - | 3 | Jun 6, 2022 | |
| CRIS Curis | Downgrades: Market Perform | n/a | $16.36 | - | 2 | Apr 5, 2022 | |
| TARS Tarsus Pharmaceuticals | Maintains: Strong Buy | n/a | $36.85 | - | 2 | Oct 8, 2021 | |
| SAGE Sage Therapeutics | Downgrades: Market Perform | n/a | $13.94 | - | 1 | Dec 1, 2020 | |
| AMGN Amgen | Upgrades: Outperform | n/a | $311.29 | - | 3 | Oct 26, 2020 | |
| VYGR Voyager Therapeutics | Assumes: Buy | n/a | $8.81 | - | 2 | Sep 10, 2018 | |
| JNJ Johnson & Johnson | Downgrades: Sell | n/a | $149.27 | - | 1 | Jul 21, 2017 |
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $16.83
Upside: +167.38%
Blueprint Medicines
Dec 22, 2023
Maintains: Strong Buy
Price Target: $85 → $100
Current: $107.19
Upside: -6.71%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $40.20
Upside: -25.37%
bluebird bio
Nov 8, 2023
Maintains: Outperform
Price Target: $10 → $13
Current: $0.90
Upside: +1,344.77%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $957.00
Upside: -0.73%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $7.53
Upside: +72.64%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $27.83
Upside: +65.29%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $29.09
Upside: +137.19%
G1 Therapeutics
May 4, 2023
Maintains: Outperform
Price Target: $24 → $8
Current: $4.49
Upside: +78.17%
Relay Therapeutics
Apr 19, 2023
Upgrades: Strong Buy
Price Target: $29
Current: $7.04
Upside: +311.93%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $1.70
Upside: +370.59%
Xilio Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $31 → $13
Current: $1.18
Upside: +1,001.69%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $6.17
Upside: +126.90%
Xencor
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $24.11
Upside: +140.56%
Simulations Plus
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $46.72
Upside: +49.83%
Allogene Therapeutics
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.97
Upside: -
Cytokinetics
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $65.27
Upside: -3.48%
Bristol-Myers Squibb Company
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $43.99
Upside: -
Curis
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $16.36
Upside: -
Tarsus Pharmaceuticals
Oct 8, 2021
Maintains: Strong Buy
Price Target: n/a
Current: $36.85
Upside: -
Sage Therapeutics
Dec 1, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $13.94
Upside: -
Amgen
Oct 26, 2020
Upgrades: Outperform
Price Target: n/a
Current: $311.29
Upside: -
Voyager Therapeutics
Sep 10, 2018
Assumes: Buy
Price Target: n/a
Current: $8.81
Upside: -
Johnson & Johnson
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $149.27
Upside: -